A committee of nephrologists and cardiologists developed 6 recommendations to improve hyperkalemia management.
Low or intermediate score on Short Physical Performance Battery linked to increased risks for composite, individual CVD outcomes.
In the US, prevalence of CV risk factors and disease set to decrease for Whites and increase for racial/ethnic minorities.
Risk for CVD, heart failure, and stroke significantly increased after adjustment for cardiovascular risk factors.
Researchers conducted a population-based cohort study involving patients with T2D aged 18 years and older initiating treatment with SGLT-2i or metformin.
The American College of Cardiology has published guidelines for managing adult patients with cardiovascular sequelae after COVID-19 infection.
Researchers sought to evaluate the relationship between initiation of metformin and sulfonylurea therapy and clinical outcomes in patients with HF and diabetes.
Sodium-glucose cotransporter-2 inhibitors recommended for HF with reduced, mildly reduced ejection fraction.
Researchers compared heart transplant candidates and patients considering mechanical circulatory support to determine differences in health-related quality of life.
The approval was based on data from the phase 3 EMPEROR-Preserved trial.
Aspirin use was associated with increased risk for incident heart failure among individuals with or without a history of cardiovascular disease
Findings for both out-of-hospital and in-hospital ST-segment elevation myocardial infarction.
It has been estimated that cardiovascular disease (CVD) claims 18.6 million lives per year. As World Heart Day seeks to raise awareness on CVD prevention and management, what are some ways your patients can reduce their risk?
Echocardiographic phenotypes significantly improved the prognostic performance on top of the ARIC HF risk score, and discriminative values were “consistently observed on top of traditionally defined cardiac structure or function abnormalities.”
The risk for recurrent MACE was high among survivors of a first ever acute coronary syndrome with a substantial number of these being fatal; 34.4% had MACE within 1 year and 48.4% in 3 years.
This study evaluated the effects of hemodynamic-guided management of heart failure on composite mortality and heart failure events.
The authors describe how to diagnose and treat patients with heart failure who develop COVID-19 disease in this case study.
The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.
Researchers determined the effects of early rhythm control therapy in patients diagnosed with atrial fibrillation with signs and symptoms of heart failure.
46 percent of those diagnosed in acute care had potential heart failure symptoms in previous six months.